LOS ANGELES--(BUSINESS WIRE)--Cougar Biotechnology, Inc. (OTCBB: CGRB) today announced that results from ongoing Phase I and Phase II clinical trials of Cougar’s investigational drug CB7630 (abiraterone acetate) were presented at the Prostate Cancer Foundation Scientific Retreat on October 11th. The Prostate Cancer Foundation Scientific Retreat is currently taking place in Lake Tahoe, Nevada.
